Not Yet RecruitingNot Applicable

Real-World Data Collection of the GORE Devices When Used in the Treatment of Aortic Pathologies Which Requires the Incorporation of the Visceral Arteries.

400 participantsStarted 2026-12

Plain-language summary

The registry population consists of patients presenting with complex aortic pathologies amenable to endovascular aortic repair that requires the incorporation of bridging stents to maintain visceral artery perfusion

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Informed Consent Form (ICF) is signed by Subject.
✓. Age ≥ 18 years at time of informed consent signature.
✓. Patient presents with thoracoabdominal, pararenal, juxtarenal, or short-neck infrarenal aortic pathology suitable for endovascular repair.
✓. Patient requires the incorporation of ≥ 1 visceral artery and is suitable for use of at least 1 GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (BXB) as a bridging stent (Note: Up to five (5) visceral arteries may be incorporated).
✓. Patient is willing to adhere to the institutional standard of care follow-up.

Exclusion criteria

✕. Patient has a prior visceral artery stenting.
✕. Patient treated for acute or sub-acute dissection, \<90 days from onset of symptoms
✕. Patient is intended to be treated with a parallel grafting (e.g., chimney, periscope, sandwich) or octopus technique.
✕. Known hypersensitivity to heparin or a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II.
✕. Patient has known coagulation disorders including hypercoagulability that are not amenable to treatment.
✕. Patient has a life expectancy \< 1-year.
✕. Patient is participating in an investigational study which may confound registry results, unless approved by Gore

What they're measuring

Freedom from Target Vessel Instability

Timeframe: through 1 year Follow-up

Trial details

NCT IDNCT07480395

SponsorW.L.Gore & Associates

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2031-12

View on ClinicalTrials.gov More Complex Aortic Aneurysms trials